Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Kidney Cancer Clinical Trial

Official title:

Phase II Study of Sunitinib in Patients With Metastatic Papillary Renal Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00459875
• Other study ID #: 07-019
• Secondary ID: P30CA008748MSKCC
• Status: Completed
• Phase: Phase 2
• First received: April 11, 2007
• Last updated: October 26, 2015
• Start date: March 2007
• Est. completion date: November 2010

Study information

• Verified date: October 2015
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with locally recurrent or metastatic kidney cancer.

Description:

OBJECTIVES:

Primary

• Determine the efficacy of sunitinib malate in patients with locally recurrent or metastatic papillary renal cell carcinoma.

OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 28 days and every 2 months thereafter.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed advanced renal cell carcinoma of papillary or other non-clear cell histology

• Metastatic or locally recurrent disease

• Measurable disease, defined as = 1 unidimensionally measurable lesion = 20 mm by conventional techniques or = 10 mm by spiral CT scan

• The following are considered nonmeasurable disease:

• Bone lesions

• Ascites

• Peritoneal carcinomatosis or miliary lesions

• Pleural or pericardial effusions

• Lymphangitis of the skin or lung

• Cystic lesions

• Irradiated lesions

• Patients with primary tumor in place who are eligible for surgery must have undergone prior partial or radical nephrectomy

• No history of or known brain metastases, spinal cord compression, or evidence of symptomatic brain or leptomeningeal carcinomatosis

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%

• Absolute neutrophil count = 1,500/mm³

• Platelet count = 100,000/mm³

• Hemoglobin = 9.0 g/dL

• Calcium = 12.0 mg/dL

• Creatinine = 1.5 times upper limit of normal (ULN)

• Bilirubin = 1.5 times ULN

• AST and ALT = 2.5 times ULN (5 times ULN if liver function abnormalities are due to underlying malignancy)

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No hemorrhage = grade 3 within the past 4 weeks

• No diagnosis of any second malignancy within the past 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer

• None of the following within the past 6 months:

• Myocardial infarction

• Severe or unstable angina

• Coronary or peripheral artery bypass graft

• Symptomatic congestive heart failure

• Cerebrovascular accident or transient ischemic attack

• Pulmonary embolism

• No ongoing cardiac dysrhythmias = grade 2 or atrial fibrillation of any grade

• No prolongation of the QTc interval to > 450 msec (males) or > 470 msec (females)

• No uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg despite optimal medical therapy)

• No pre-existing thyroid abnormality, with thyroid function tests that cannot be maintained in the normal range with medication

• No known HIV or AIDS-related illness

• No other active infection

• No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study compliance

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior sunitinib malate

• Prior or concurrent bisphosphonates allowed

• More than 4 weeks since prior radiotherapy and recovered

• Prior palliative radiotherapy to metastatic lesions allowed provided there is = 1 measurable lesion that has not been irradiated

• More than 4 weeks since prior major surgery and recovered

• No concurrent therapeutic doses of warfarin

• Low-dose warfarin = 2 mg daily for thromboprophylaxis allowed

• Concurrent low molecular weight heparin for full anticoagulation allowed

• No other concurrent approved or investigational anticancer treatment, including chemotherapy, biological response modifiers, hormonal therapy, or immunotherapy

• No other concurrent investigational drugs

• No concurrent treatment on another clinical trial

• Concurrent participation on supportive care trials or nontreatment trials (e.g., quality of life trials) allowed

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Cancer
• Kidney Neoplasms

Intervention

Drug:
• sunitinib malate

Locations

Country	Name	City	State
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs. 2012 Feb;30(1):335-40. doi: 10 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Objective Response Rate as Measured by RECIST		2 years	No